Search filters

List of works by Michael Hanna

Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial

scientific article published on 01 October 2014

Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

scientific article published on 22 December 2016

Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial

scientific article published on 7 November 2016

Antithrombotic Therapy Use and Clinical Outcomes Following Thromboembolic Events in Patients with Atrial Fibrillation: Insights from ARISTOTLE.

scientific article published on 29 January 2018

Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial

scientific article published on 27 July 2016

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial ⬇️

scientific article published on May 8, 2012

Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale

scientific article published in March 2010

Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

scientific article published on 23 June 2015

Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial

scientific article

Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial

scientific article published on 25 July 2013

Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial

scientific article published on 20 October 2013

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy

scientific article published on 01 August 2018

Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation

scientific article published on 02 February 2016

Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial

scientific article published on December 2015

Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial

scientific article published on 6 November 2017

Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial

scientific article published on 28 September 2014

Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial

scientific article published on 12 December 2014

Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial

scientific article published on 14 September 2015

Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial

scientific article published on 01 April 2015

Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation

scientific article

Digoxin and Mortality in Patients With Atrial Fibrillation

scientific article published in March 2018

Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial

Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Tria

scientific article

Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin

scientific article

Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect

scientific article published on 18 May 2017

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation

scientific article published on 12 September 2018

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

scientific article published on 17 January 2017

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial

scientific article published on July 2016

Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight

scientific article published on 01 May 2019

Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial

scientific article published on 21 July 2017

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial

scientific article

Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.

scientific article published on 2 May 2013

Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE

scientific article published on 06 June 2014

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

scientific article published on 09 April 2019

Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial

scientific article published on 29 August 2012

Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARI

scientific article published on 07 October 2014

High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin

scientific article published on 19 September 2013

History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.

scientific article

Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial

scientific article published on 01 April 2019

International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin

scientific article published on 01 July 2019

Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy

scientific article published on 29 March 2017

Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial

scientific article published on 10 April 2013

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin

article

Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures

scientific article

N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).

scientific article published on 3 April 2013

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation

scientific article

Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial

article published in 2018

Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease

scientific article published on 19 January 2018

Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial

scientific article published on 17 April 2013

Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation

scientific article published on 16 September 2020

Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial

scientific article published on 30 December 2019

Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time

scientific article

Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation".

scientific article

The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.

scientific article

The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation

scientific article published on 25 February 2016

Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation

scientific article published on 01 October 2018

Paulina is supported by:

About Paulina

Help